After Tumor Resection, What Must Be Rebuilt?

Cancer Has Become Harder to Think of as Someone Else’s Disease

Over the past two years, several people in my own circle have been diagnosed with cancer.

Personal experience is not epidemiology. But it changes how epidemiology feels.

A diagnosis that once seemed distant begins to appear in conversations with friends, colleagues and families. It raises an uncomfortable question: Are we really seeing more cancer?

China’s cancer burden is substantial. The National Cancer Center of China estimated approximately 5.15 million new cancer cases and 2.58 million cancer deaths in 2024. Lung, thyroid, colorectal, breast and liver cancers account for a large proportion of the national burden.

That overall picture matters. But it also needs context.

The vast majority of people with cancer will never require an orthopedic tumor prosthesis. Primary malignant bone tumors and many bone and soft-tissue sarcomas are relatively uncommon compared with lung, colorectal, breast, liver or gastric cancers.

This page therefore addresses a much narrower clinical question:

What happens when a tumor involves bone or a joint so extensively that oncologic resection leaves a major skeletal and soft-tissue defect?

For these patients, treatment does not end when the tumor is removed.

A second problem begins.

How do we reconstruct what the operation had to take away?

Quick Answer: What Is Tumor Reconstruction?

Orthopedic tumor reconstruction is the restoration of skeletal continuity, fixation, joint mechanics and, where possible, soft-tissue function after oncologic resection.

In practical terms, the reconstructive team may need to restore four interconnected elements:

Reconstruction Domain	Core Clinical Question
Structure	Can continuity of the limb or pelvis be restored after segmental bone resection?
Fixation	Where is the remaining reliable host bone, and how will the construct transfer load?
Joint Mechanics	How will length, joint center, rotation, stability and motion be reconstructed?
Soft Tissue	Where will the remaining muscles, tendons and capsule attach and function?

This distinction matters because tumor reconstruction is not simply “replacing the amount of bone that was removed.”

It is the reconstruction of a working biomechanical system.

China Was Describing Abnormal Masses Long Before Modern Oncology Existed

China has one of the world’s oldest continuous medical traditions, and abnormal masses were described in Chinese medical texts more than two thousand years ago.

Classical terms including ji ju, zheng jia, shi jia and later descriptions involving yan were used for persistent masses, swellings or abnormal growths.

These historical descriptions are medically interesting, but they require restraint.

They cannot be mapped one-to-one onto modern cancer diagnoses.

A mass described in an ancient text might today be classified as a benign tumor, malignant tumor, cyst, inflammatory lesion, organ enlargement or another disease entirely. Ancient physicians did not have histopathology, immunohistochemistry, CT, MRI, molecular testing or contemporary tumor staging.

The significance of those early observations is therefore not that ancient medicine had already defined “cancer” in the modern sense.

It is that physicians had recognized a fundamental biological problem:

tissue could form an abnormal, persistent and sometimes destructive mass that no longer behaved like healthy anatomy.

Modern oncology transformed that observation into something measurable.

Today clinicians can ask:

What tissue did the lesion arise from?

What is its histologic grade?

How far has it extended?

Are neurovascular structures involved?

Is metastatic disease present?

What margin is required?

And after that margin is achieved:

What anatomy will remain?

That final question is where orthopedic oncology and reconstruction meet.

The First Principle: Oncologic Clearance Defines the Defect

Every discussion of tumor prostheses should begin here.

Oncologic clearance defines the defect. Reconstruction must adapt to it—not the other way around.

The implant does not define the tumor margin.

A 3D-printed device does not define the tumor margin.

A robot does not define the tumor margin.

A modular stem does not define the tumor margin.

The oncologic strategy comes first.

For appropriately selected patients with extremity bone sarcoma, limb-salvage surgery can be considered when an oncologically appropriate resection can be achieved. Depending on the defect and the patient, reconstruction may involve a megaprosthesis, allograft, autograft, biological reconstruction, composite reconstruction or another strategy.

Limb salvage is therefore not synonymous with megaprosthetic reconstruction.

Nor should preservation of the limb override tumor control.

The correct sequence is:

Diagnosis → Staging → Multidisciplinary Planning → Oncologic Resection → Definition of the Actual Defect → Reconstruction

That sequence protects an essential ethical boundary.

The reconstruction exists to solve the defect created by appropriate tumor treatment.

The tumor operation should not be compromised to accommodate the reconstruction.

After Resection, More Than Bone Is Missing

Consider a patient who undergoes resection of a large proximal femoral tumor.

The postoperative radiograph may make the missing bone look like the dominant problem.

But biologically and mechanically, the operation may have altered much more:

bone continuity, limb length, hip center, femoral rotation, load transfer, abductor mechanics, tendon insertions, capsule, muscle attachments and joint stability.

The same principle applies around the knee.

A distal femoral or proximal tibial tumor may require removal not only of a segment of bone, but also of native articular surfaces and structures that previously contributed to stability and movement.

That is why the question:

“How many centimeters of bone were removed?”

is necessary but insufficient.

The more useful question is:

What functions were removed with that bone, and which of them can realistically be reconstructed?

Structure: Rebuilding Skeletal Continuity

Segmental tumor resection can create a defect too large for a conventional primary joint implant.

This is the environment in which modular tumor systems become relevant.

The reconstructive team must consider the final resection length, remaining bone, medullary geometry, potential fixation zone, whether the joint has been preserved or removed, and how the completed construct will transfer load.

One important reason for modularity is simple:

the defect that exists after the final oncologic resection is the defect that must be reconstructed.

Preoperative imaging can estimate that defect. Surgical planning can model it. Patient-specific guides can help reproduce a plan.

But the definitive anatomy is still established in the operating room.

AK Medical’s AK-THS Tumor Femoral Stem product information describes titanium-alloy modular components, conical locking between components, multiple extension-stem specifications for intraoperative assembly, tendon suture holes in the proximal and lesser-trochanteric regions, and a vacuum-plasma pure-titanium coating on the proximal prosthetic surface.

The important clinical concept is not simply that “more modules provide more choices.”

It is that modularity can provide a controlled way to configure the reconstruction after the final extent of bone loss is known.

Modularity is useful when it answers a reconstructive variable.

Complexity by itself has no clinical value.

Fixation: The Most Important Question May Be “Where Is the Good Bone?”

In major reconstruction, implant length can be visually impressive.

But length alone does not define fixation.

A more useful question is:

Where is the remaining host bone capable of supporting the reconstruction?

That question changes how the entire case is viewed.

The surgeon may need to evaluate residual cortical bone, canal morphology, bone quality, previous surgery, resection level and the available region for axial and rotational support.

The construct then has to connect the reconstructed segment to that remaining anatomy in a mechanically coherent way.

In oncology patients, the biological environment may be complicated further by systemic treatment, nutritional status, soft-tissue injury, previous surgery or radiation exposure.

This is why implant features should not be converted automatically into clinical-outcome claims.

For example, a modular junction can be described as part of the system’s assembly strategy.

A surface treatment can be described according to its intended interface.

A stem can be described according to its geometry.

But without product-specific clinical evidence, those features should not be translated into claims such as:

“lower loosening rates,”

“greater survivorship,”

or

“faster functional recovery.”

That distinction is especially important on professional product pages.

Engineering rationale and demonstrated clinical outcome are not the same category of evidence.

Joint Mechanics: A Tumor Knee Is Not Simply a Longer Total Knee Replacement

Tumors around the distal femur and proximal tibia create a particularly demanding reconstructive problem.

In primary total knee arthroplasty, the surgeon usually reshapes and resurfaces an existing joint while much of the femur, tibia and surrounding soft-tissue architecture remains present.

After segmental oncologic resection, that assumption may no longer apply.

Part of the native joint and an adjacent segment of bone may be gone.

The reconstruction must therefore recreate a load-bearing articulation while simultaneously addressing length, axis, rotation and stability.

AK Medical’s product information identifies an AK-TKS Tumor Condylar component in Co-Cr-Mo alloy, an AHK tibial insert in UHMWPE and an AK-TKS tibial tray in Co-Cr-Mo alloy as components within its knee tumor reconstruction offering.

The clinically relevant question is not simply what those components are made from.

It is:

How can a stable articulation be reconstructed when both joint anatomy and a segment of supporting bone have been removed?

This is the conceptual difference between routine arthroplasty and segmental tumor reconstruction.

The first mainly reconstructs an arthritic joint.

The second may need to reconstruct the joint and the missing skeleton around it at the same time.

The Forgotten Reconstruction: Muscle and Tendon Attachment

One of the most important lessons in tumor reconstruction is also one of the easiest to overlook:

a metal implant does not move a limb.

Muscles do.

Tendons transmit force.

The capsule and remaining soft tissues contribute to stability.

Nerves make coordinated movement possible.

This becomes particularly relevant in proximal femoral reconstruction.

Large resections may affect structures involved in abductor function, hip stability and soft-tissue tension. A technically stable implant can therefore coexist with substantial functional limitation if the biological motor system around it has been compromised.

AK-THS product information describes tendon suture holes around the proximal and lesser-trochanteric regions and a proximal vacuum-plasma pure-titanium coating.

For a professional audience, the wording around these features matters.

It is reasonable to say that such design elements provide options relevant to soft-tissue handling and attachment during reconstruction.

It would be inappropriate, without direct product-specific clinical evidence, to claim that these features guarantee muscle restoration, lower dislocation rates or superior long-term function.

That evidence boundary is important because patient function depends on far more than the implant.

It depends on what the tumor allowed the surgeon to preserve.

It depends on nerve integrity.

It depends on muscle quality.

It depends on soft-tissue coverage.

It depends on rehabilitation.

And it depends on the patient’s overall cancer treatment.

A useful principle is:

A megaprosthesis may restore skeletal continuity. Functional recovery still depends on the biological tissues that remain around it.

When Does Modular Tumor Reconstruction Make Sense?

Modular megaprosthetic reconstruction may be considered when oncologic resection creates a major structural defect that cannot be managed adequately with a conventional primary implant and when a prosthetic reconstruction can provide an appropriate structural pathway using the remaining anatomy.

That does not mean it is automatically the preferred solution.

The reconstructive strategy has to be evaluated in the context of tumor type, stage, expected resection, residual bone, neurovascular status, age, biological reconstruction alternatives, expected systemic therapy, infection risk, functional goals and long-term prognosis.

This is particularly important in younger patients, where long-term reconstructive implications can extend over decades.

A strong orthopedic oncology platform therefore should not ask:

“Which implant can we put in?”

It should ask:

“Which reconstruction is justified for this patient after an appropriate oncologic resection?”

The difference is fundamental.

Not Every Complex Tumor Defect Needs a Custom 3D-Printed Implant

Patient-specific reconstruction has expanded what is technically possible in pelvic and complex limb-salvage surgery.

But “technically possible” is not the same as “clinically necessary.”

This distinction is especially important now that additive manufacturing is increasingly associated with sophisticated orthopedic reconstruction.

A 3D-printed implant may still be completely standardized.

A patient-matched plan may use only standard implants.

A patient-specific instrument may be customized while the permanent implant remains standard.

And a true patient-specific implant is designed for one patient’s anatomy and reconstruction strategy.

AK Medical’s ICOS documentation makes this distinction explicit. ICOS is described as a surgeon-engineer platform connecting imaging, 3D reconstruction, surgical planning, patient-specific implant or instrument design, engineering verification, manufacturing and surgical execution. It also states that patient-specific reconstruction should not replace standard implants when standard cups, cones, sleeves, augments, stems or tumor systems can provide reliable reconstruction.

For tumor reconstruction, that creates a clinically useful escalation pathway:

Standard when possible. Modular when necessary. Patient-specific when required.

Patient-specific reconstruction may become particularly relevant when tumor resection produces unusual pelvic geometry, irregular multiplanar bone loss, limited fixation zones, complex screw corridors, altered anatomy after previous procedures or a defect that standard components cannot adequately bridge.

ICOS materials further emphasize that tumor reconstruction is different from routine revision because the resection is defined by oncologic margins rather than implant geometry, and planning may need to incorporate resection planes, remaining bone, fixation, joint center, soft-tissue attachment and surgical execution.

That is precisely where surgeon-engineer collaboration can become valuable.

But the core principle remains:

Complex geometry is not inherently better. Every flange, hole, porous region and interface should have a clinical or engineering purpose.

Why Tumor Reconstructions Fail

A professional tumor reconstruction page should not discuss only what a megaprosthesis is designed to accomplish.

It should also acknowledge how these reconstructions can fail.

The complication profile varies by anatomical location, diagnosis, surgical extent, host factors, implant design, follow-up duration and treatment pathway. Across the orthopedic oncology literature, several failure mechanisms repeatedly deserve attention.

Infection

Large resections frequently require longer operations, extensive dissection and major implants. Soft-tissue coverage may be compromised, and systemic therapy can further complicate the biological environment.

Periprosthetic infection is therefore one of the most serious complications in megaprosthetic reconstruction.

Aseptic Loosening

Long-term fixation depends on host bone, implant geometry, load transfer, fixation strategy and patient biology.

No surface treatment or stem design eliminates the need to assess whether adequate host bone exists.

Mechanical Failure

Large reconstructive constructs operate under repeated cyclic loading.

Modularity provides valuable intraoperative flexibility, but each modular interface also has to be assembled, locked and managed according to the approved system technique.

Soft-Tissue Failure and Instability

A successful skeletal reconstruction does not guarantee a successful soft-tissue reconstruction.

Muscle loss, tendon insufficiency, capsular deficiency and altered lever arms can affect stability and function.

Local Tumor Recurrence

This requires a different conceptual category.

Local recurrence is fundamentally an oncologic problem, not an implant-performance claim.

Tumor biology, stage, surgical margin and multidisciplinary cancer treatment remain central.

A reconstruction system should never be positioned as a technology that prevents oncologic recurrence unless such a claim has been directly demonstrated and appropriately authorized.

Limb Salvage Should Mean More Than Keeping the Limb

The phrase limb salvage is powerful.

But it can become misleading if the clinical goal is reduced to “the limb was not amputated.”

For patients, the questions are more personal:

Can I stand?

Can I walk without another person holding me?

Can I return to school?

Can I work?

Can I climb stairs?

Can I care for my family?

Can I live independently?

This is why modern orthopedic oncology increasingly considers function and health-related quality of life alongside local tumor control and survival.

A postoperative radiograph can show the reconstruction.

It cannot show what that reconstruction means in the patient’s daily life.

That gap between radiographic reconstruction and functional reconstruction is one of the most important realities in tumor surgery.

AK Medical Tumor Reconstruction: A Reconstruction Continuum, Not a Single Implant

AK Medical’s tumor reconstruction portfolio should be understood as a continuum rather than a single-device story.

At the standard and modular level, the AK-THS Tumor Femoral Stem and AK Knee Tumor System provide implant pathways for selected segmental femoral and knee-region reconstructions. The reviewed product material documents modular AK-THS components, conical component locking, extension options, proximal tendon-suture features and a proximal titanium coating, together with tumor-knee femoral, polyethylene insert and tibial components.

When standard or modular reconstruction is not sufficient, ICOS extends the pathway into patient-specific planning and reconstruction. Its documentation describes a workflow that connects imaging, 3D reconstruction, surgeon-engineer collaboration, fixation planning, implant design, engineering verification, additive manufacturing, patient-specific instruments, surgery and postoperative case review.

The important message is not that every difficult tumor should move toward customization.

It is the opposite.

A mature reconstruction strategy should preserve simplicity whenever simplicity is sufficient.

The hierarchy should remain:

Oncologic Safety → Appropriate Reconstruction → Reliable Fixation → Functional Restoration → Appropriate Technology

Technology belongs at the end of that chain, not at the beginning.

A More Complete Tumor Reconstruction Pathway

A clinically coherent orthopedic oncology pathway can be expressed as:

Diagnosis and Histology

→ Tumor Staging

→ Multidisciplinary Review

→ Oncologic Resection Planning

→ Definition of Bone and Soft-Tissue Defect

→ Reconstruction Strategy

→ Fixation Planning

→ Joint Mechanics Restoration

→ Soft-Tissue Reconstruction

→ Rehabilitation

→ Long-Term Oncologic and Implant Surveillance

An implant participates in this pathway.

It does not replace it.

Neither does 3D printing.

Neither does digital planning.

Neither does engineering.

The clinical team remains responsible for diagnosis, resection, reconstruction and patient care.

ICOS documentation similarly emphasizes that engineers translate the surgeon-approved clinical objectives into geometry, fixation pathways and manufacturing parameters; the surgeon remains responsible for the clinical plan.

That boundary is not a limitation of technology.

It is what makes responsible technology possible.

Frequently Asked Questions

What is orthopedic tumor reconstruction?

Orthopedic tumor reconstruction is the restoration of skeletal structure and, where possible, function after tumor resection. Depending on the case, it may address segmental bone loss, fixation, joint reconstruction, limb length, soft-tissue attachment and load transfer.

What is a tumor megaprosthesis?

A megaprosthesis is a large reconstructive implant designed to replace a major segment of bone and, in many cases, an adjacent joint. It is used in selected tumor reconstructions and may also be used in some extreme trauma or revision situations.

Is limb-salvage surgery always preferable to amputation?

No. Limb salvage is appropriate only when an oncologically acceptable resection and a clinically meaningful reconstruction can be achieved. Tumor control remains the first priority.

Why is soft-tissue reconstruction important after proximal femoral tumor resection?

Because hip function depends on more than skeletal continuity. Tumor resection may affect muscles and tendons involved in stability, gait and abductor function. The remaining soft tissues and their reconstruction can significantly influence functional recovery.

What is the difference between modular and patient-specific tumor reconstruction?

A modular system combines predefined implant components to create the required reconstruction. A patient-specific implant is designed for one patient’s remaining anatomy and surgical plan. Patient-specific reconstruction is generally most relevant when standard or modular options cannot provide adequate fit, fixation or structural restoration.

Is every 3D-printed implant custom made?

No. Additive manufacturing is a manufacturing method. A 3D-printed implant can be standardized, patient matched or truly patient specific. ICOS documentation explicitly distinguishes these categories.

When may patient-specific reconstruction be considered after tumor resection?

It may be considered when the remaining anatomy is too irregular for standard components, fixation corridors are limited, pelvic or multiplanar defects are complex, or conventional tumor systems cannot adequately restore structural continuity, joint relationships or fixation.

What are the major risks after megaprosthetic tumor reconstruction?

Important risks described in orthopedic oncology literature include infection, aseptic loosening, mechanical failure, soft-tissue insufficiency, instability and reoperation. Tumor recurrence remains primarily an oncologic issue rather than an implant-performance outcome.

Does an advanced implant guarantee better function?

No. Functional outcome depends on tumor biology, resection extent, remaining muscle and nerve function, fixation, soft-tissue reconstruction, complications, systemic treatment, rehabilitation and patient factors. Implant design is only one part of the final result.

Reconstructing More Than Bone

More than two thousand years ago, Chinese physicians could describe an abnormal mass, follow its growth and recognize that something inside the body was no longer behaving normally.

Today we have histopathology, CT, MRI, molecular medicine, chemotherapy, modern surgical oncology, modular megaprostheses, additive manufacturing and patient-specific reconstruction.

Medicine has changed profoundly.

But the human question at the center of tumor treatment remains remarkably simple:

How much disease can we safely remove, and how much of the person can we help preserve?

For a patient with a major bone tumor, resection may be the first battle.

Then comes another one:

standing again,

walking again,

returning home,

returning to work,

and recovering as much independence as the disease and treatment will allow.

That is why the right question after tumor resection is not only:

How much bone was removed?

It is:

What must be rebuilt for this person to live again?

Tumor reconstruction is ultimately not the replacement of a missing segment.

It is an attempt to reconnect anatomy with function—and treatment with life.

Selected References

1. National Cancer Center of China. National estimates of cancer incidence and mortality in China, 2024.

2. National Cancer Institute. Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®).

3. AK Medical. Tumor Reconstruction product information: AK-THS Tumor Femoral Stem and AK Knee Tumor System.

4. AK Medical. ICOS Patient-Specific Orthopedic Reconstruction: When Standard Implants Are Not Enough.

5. Xu L, Wang Y, Wang J, et al. Clinical study of 3D-printed personalized prosthesis in the treatment of bone defect after pelvic tumor resection. Journal of Orthopaedic Translation. 2021;29:163–169.

6. Wu J, Xie K, Luo D, et al. Three-dimensional printing-based personalized limb salvage and reconstruction treatment of pelvic tumors. Journal of Surgical Oncology. 2021;124:420–430.

Important Medical and Regulatory Information

This page is intended for orthopedic surgeons, multidisciplinary tumor teams, hospitals and professional medical-device partners. Tumor systems, modular components, patient-matched products, patient-specific implants and patient-specific instruments may have different indications, configurations, materials and regulatory status by country.

Before publication for the United States, European Union, United Kingdom or another market, the current regulatory status, approved labeling, Instructions for Use, component compatibility and product availability should be verified for each specific product and indication.

Patient-specific technology does not replace oncologic principles, infection control, multidisciplinary review or clinical judgment. Published evidence from other manufacturers or institutions may explain category-level reconstruction principles but should not be attributed to a specific AK Medical device unless that device was directly evaluated.